1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

09/08/2026, 2:37 PM • The Motley Fool

If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King

Abbott Laboratories, a Dividend King with 54 consecutive years of dividend increases, is positioned as a defensive investment for potential market downturns. The company reported strong Q2 results with 13% sales growth and raised its full-year EPS guidance. With a 46% payout ratio and growth catalysts from medical devices and its $21 billion Exact Sciences acquisition in cancer diagnostics, Abbott offers both income stability and growth potential.

09/08/2026, 5:15 AM • The Motley Fool

Where Will SCHD Stock Be in 5 Years?

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech exposure (8.2%) means it will miss out on AI-driven gains that boosted the Nasdaq-100 by 92%. The outlook remains positive for the next five years if the U.S. economy continues growing, though trade policy uncertainty and rising bond yields present near-term risks.

09/06/2026, 12:23 PM • The Motley Fool

Schwab U.S. Dividend Equity vs. Vanguard Dividend Appreciation: Which ETF Looks Better for Your Portfolio?

Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.

09/05/2026, 8:15 AM • The Motley Fool

Baby Food & Infant Formula Market Size to Reach USD 74.30 Billion by 2035 | Report by SNS Insider

The global Baby Food and Infant Formula Market was valued at USD 40.37 billion in 2025 and is projected to reach USD 74.30 billion by 2035, growing at a CAGR of 6.29%. Growth is driven by urbanization, increasing parental health consciousness, demand for organic/premium products, and e-commerce expansion. However, recent product recalls by major manufacturers highlight safety concerns in the industry.

09/04/2026, 6:30 PM • GlobeNewswire

Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.

09/04/2026, 10:54 AM • GlobeNewswire

If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio

As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.

09/02/2026, 2:05 PM • The Motley Fool

If I Could Only Buy and Hold 1 Dividend ETF Forever, Here's What I'd Choose

A Motley Fool contributor recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a single buy-and-hold dividend investment. The ETF tracks 100 U.S. stocks with consistent dividend histories and strong fundamentals, features an ultra-low 0.06% expense ratio, and holds well-known companies like Home Depot, Merck, and Procter & Gamble with evenly weighted top holdings to diffuse risk.

09/02/2026, 11:30 AM • The Motley Fool

National Advertising Division Finds Certain Kendamil Infant Formula Claims Supported; Recommends Others Be Modified or Discontinued

The National Advertising Division ruled on a challenge by Abbott Laboratories against Kendamil infant formula. While NAD supported claims about whole milk ingredients, it recommended Kendamil discontinue or modify claims regarding nutritional superiority over competitors, breast milk comparisons, HMO immune health benefits, and brand heritage dating to 1962. Kendamil stated it will comply with NAD's recommendations.

08/31/2026, 10:00 AM • GlobeNewswire

Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.

08/31/2026, 5:04 AM • GlobeNewswire

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

08/27/2026, 1:00 PM • GlobeNewswire

Laboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider

The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

08/27/2026, 11:00 AM • GlobeNewswire

Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

08/26/2026, 7:57 AM • GlobeNewswire

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.

Billionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.

08/26/2026, 6:20 AM • The Motley Fool

Intravascular Lithotripsy Market Size to Reach USD 4.19 Billion by 2035 as Coronary and Peripheral IVL Adoption Accelerates – SNS Insider

The global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.

08/25/2026, 11:59 AM • GlobeNewswire